Pregnenolone

Pregnenolone is being investigated as a therapeutic agent across several clinical conditions, with completed and ongoing Phase 1 and Phase 2 trials examining its potential benefits.

Substance Use Disorders

Clinical trials have explored pregnenolone's role in treating substance dependencies. A completed Phase 2 trial (NCT02439814) investigated pregnenolone for marijuana dependence, while another Phase 1 study (NCT03872128) examined the relationship between neuroactive steroids, stress, alcohol craving, and alcohol use in individuals with alcohol use disorders. Currently, a Phase 2 trial (NCT05781009) is actively recruiting participants to evaluate pregnenolone as a treatment for alcohol use disorder, indicating continued research interest in this application.

Chronic Pain Management

A completed Phase 2 trial (NCT01898013) specifically examined pregnenolone as a novel therapeutic agent for chronic pain in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) veterans. This suggests potential applications for pain management, particularly in veteran populations who may have service-related chronic pain conditions.

Traumatic Brain Injury

Research has investigated pregnenolone as an adjunctive treatment for mild traumatic brain injury (TBI) in veterans (NCT00623506), though this was not a formal phase trial. This application aligns with pregnenolone's role as a neurosteroid and its potential neuroprotective properties.

Neurological and Endocrine Research Context

Recent research publications indicate ongoing investigation into pregnenolone's role in various physiological processes. Studies have examined its involvement in steroidogenic pathways, GABAergic neurotransmission related to epilepsy, and metabolic profiling in conditions like polycystic ovary syndrome. Research has also identified pregnenolone enrichment in certain pituitary neuroendocrine tumors, suggesting potential biomarker applications.

Current Evidence Limitations

While pregnenolone shows promise across multiple therapeutic areas, the clinical evidence remains limited to early-phase trials. Most completed studies appear to be small-scale Phase 1 or Phase 2 investigations, and comprehensive efficacy data from large randomized controlled trials are not yet available in the provided evidence.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Consult with a healthcare provider before considering any neurosteroid therapy.